Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma BiomarkersNiklas Mattsson, Oskar Hansson, Rebecca Langhough et al.|JAMA Neurology|2023Cited by 293
Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission TomographyGillian Coughlan, Rachel F. Buckley, Tobey J. Betthauser et al.|JAMA Neurology|2023Cited by 124
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trialsRik Ossenkoppele, Oskar Hansson, Gemma Salvadó et al.|Nature Aging|2025Cited by 68
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer DiseasePontus Erickson, Prashanthi Vemuri, Joel Simrén et al.|JAMA Neurology|2023Cited by 46
The cerebrospinal fluid A‐T+ Alzheimer disease biomarker profile: prevalence and clinical relevancePontus Eriksson, Henrik Zetterberg, Joel Simrén et al.|Alzheimer s & Dementia|2023Cited by 2